Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to incorporate a prospectus supplement registering for resale up to 943,000,000 ordinary shares (represented by 1,886 ADSs). The supplement incorporates a Form 6-K describing a set of concurrent financings: a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants, concurrent private placements of 350,877 unregistered pre-funded warrants and private warrants, and related inducement warrants, subject in several cases to shareholder approval. The transactions are expected to generate aggregate gross proceeds of approximately $3.54 million before fees and are arranged with a placement agent paid an 8.0% cash fee. The supplement and Form 6-K describe exercise prices, beneficial ownership limits (4.99% or 9.99% at investor option), registration rights and customary closing conditions.
Biodexa Pharmaceuticals PLC amends its prospectus to register 109,500,000 ordinary shares (represented by 219 ADSs) for resale by selling shareholders. This Prospectus Supplement incorporates a Form 6-K describing concurrent financing arrangements including a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants at prices of $2.85 and $2.8499, respectively.
The Form 6-K also describes private placements of additional pre-funded warrants and warrants (Series M, N and O) exercisable upon shareholder approval, a warrant inducement arrangement, and an expected aggregate gross proceed estimate of approximately $3.54 million. Shareholder approval is required for the issuance and exercise of the Series M/N/O warrants.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to register the resale of 1,701,500,000 ordinary shares represented by 3,403 ADSs.
The supplement also discloses a registered direct offering of 82,809 ADSs at $2.85 per ADS and sale of 200,143 registered pre-funded warrants at $2.8499, concurrent private placements of 350,877 unregistered pre-funded warrants and unregistered warrants (Series M/N/O) exercisable subject to shareholder approval. Aggregate gross proceeds from the described transactions are expected to be approximately $3.54 million, and certain warrants have an exercise price of $0.0001 (pre-funded) or $2.85 (Series M/N/O). Several issuances and exercises are conditioned on shareholder approval and the resale registration process.
Biodexa Pharmaceuticals PLC files a prospectus supplement and Form 6-K describing completed and follow-on offerings and related warrant arrangements.
The supplement registers up to 97,800 ADSs (representing 48,900,000,000 Ordinary Shares), 1,219,512 ADSs (representing 609,756,000,000 Ordinary Shares) and 30,487 ADSs (representing 15,243,500,000 Ordinary Shares) underlying various warrants. The company completed a “best efforts” offering and separately agreed a Registered Direct Offering and private placements providing aggregate expected gross proceeds of approximately $3.54 million, subject to closing and shareholder approval.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to cover the resale of 171,500,000 Ordinary Shares represented by 343 American Depositary Shares. The supplement incorporates a Form 6-K disclosing a series of concurrent financings: a registered direct offering, private placements of pre‑funded warrants and contingent warrants, and a warrant inducement.
The company agreed to sell 82,809 ADSs at $2.85 and 200,143 Registered Pre‑Funded Warrants at $2.8499, with additional unregistered pre‑funded warrants and exercisable warrants contingent on shareholder approval. Aggregate gross proceeds are expected to be approximately $3.54 million, subject to closing conditions.
Biodexa Pharmaceuticals PLC is conducting a primary offering of 82,809 American Depositary Shares, each representing 500,000 ordinary shares, at a price of $2.85 per Depositary Share and is issuing 200,143 pre-funded warrants in lieu of certain Depositary Shares.
The prospectus supplement describes a concurrent private placement of Series M warrants exercisable for 282,952 Depositary Shares, related warrant inducement and a second private placement, and states expected gross offering proceeds, placement agent fees and estimated net proceeds to the company.
Biodexa Pharmaceuticals PLC reported the results of its rescheduled Annual General Meeting held on June 30, 2026. Ordinary resolutions 1 through 7 were approved, with voting majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, showing broad support for core business items.
Ordinary resolution 8 and special resolution 10 did not pass, and resolution 11 also failed because it was contingent on resolution 8. The company remains a clinical stage biopharmaceutical developer focused on gastrointestinal cancers and other diseases with unmet medical needs through programs such as eRapa, MTX240 and tolimidone.
Biodexa Pharmaceuticals PLC has priced a group of equity and warrant transactions expected to raise approximately $3.5 million in gross proceeds through a registered offering, a concurrent private placement and a warrant exercise inducement.
The deals combine sales of American depositary shares and pre-funded warrants at $2.85 per ADS (or $2.8499 per pre-funded warrant) with new Series M, N and O warrants that, once shareholder approval is obtained, will allow the investor to purchase additional ADSs over five years at the same exercise price. Certain existing Series L warrants will be exercised for cash at the reduced price of $2.85 in exchange for issuing Series O warrants at a 200% ratio to ADSs received.
The company has engaged Maxim Group LLC as exclusive placement and inducement agent, agreeing to pay an 8.0% cash fee on gross proceeds plus expenses, and has entered into a registration rights agreement to register resales of the warrants and the ADSs issuable upon their exercise.
Biodexa Pharmaceuticals PLC reports that its Annual General Meeting scheduled for June 17, 2026 was adjourned due to lack of a quorum. In line with its articles of association, the meeting has been re-scheduled for 11:00 a.m. London time on June 30, 2026 at the company’s Cardiff registered office.
Proxies submitted in time for the original AGM will remain valid for the new date. The company is a clinical stage biopharmaceutical business with lead programs eRapa, MTX240 and tolimidone targeting gastrointestinal cancers, Familial Adenomatous Polyposis, Non-Muscle Invasive Bladder Cancer, GIST and type 1 diabetes.